GO:0120189 positive regulation of bile acid secretion: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0120189 describes any process that activates or increases the frequency, rate or extent of the controlled release of bile acid from a cell or a tissue.
• Bile acid secretion is positively regulated by nuclear receptors, transporters, and signaling kinases that sense bile acid levels and inflammatory cues.
• Dysregulated positive regulation of bile acid secretion contributes to liver cancer, cholestasis, colorectal cancer, and metabolic disorders.
• Gut microbiota modify bile acids and influence their secretion and downstream signaling, linking GO:0120189 to host-microbe interactions.
• Key genes include NR1H4 (FXR), ABCB11 (BSEP), ABCC2 (MRP2), SLC10A1 (NTCP), and CYP7A1, which coordinate bile acid synthesis and export.
• CRISPR knockout, knock-in, and overexpression models enable causal testing of genes that positively regulate bile acid secretion.
Description
Bile acids are amphipathic molecules synthesized from cholesterol in hepatocytes and secreted into the biliary tree to facilitate lipid digestion and absorption. The controlled release of bile acids from cells or tissues is a tightly regulated process, and its positive regulation is annotated as GO:0120189, defined as any process that activates or increases the frequency, rate or extent of the controlled release of bile acid from a cell or a tissue. This process is essential for maintaining bile acid homeostasis, preventing cholestatic injury, and shaping metabolic and immune responses. Researchers study GO:0120189 because its dysregulation is linked to liver cancer, cholestasis, inflammatory bowel disease, and obesity. Bile acids also act as signaling molecules that modulate tumor-specific T cell responses and innate lymphoid cell function, making their secretion a nexus of metabolism and immunity. Understanding the positive regulation of bile acid secretion therefore has broad implications for hepatology, oncology, and metabolic disease research.
positive regulation of bile acid secretion At A Glance
| GO ID | GO:0120189 |
|---|---|
| GO term | positive regulation of bile acid secretion |
| Ontology | biological_process |
| Synonym | none |
| Major function | Activates or increases the controlled release of bile acids from cells or tissues |
| Related processes | Bile acid synthesis, transport, and signaling; enterohepatic circulation |
| Key regulators | NR1H4 (FXR), ABCB11 (BSEP), ABCC2 (MRP2), SLC10A1 (NTCP), CYP7A1 |
| Disease relevance | Liver cancer, cholestasis, colorectal cancer, obesity, ulcerative colitis |
| Research methods | CRISPR KO/knock-in, RNA-seq, proteomics, bile acid profiling |
What Is GO:0120189?
GO:0120189, positive regulation of bile acid secretion, refers to any biological process that activates or increases the frequency, rate, or extent of the controlled release of bile acids from a cell or a tissue. This includes signaling events that enhance bile acid export from hepatocytes, cholangiocytes, or enterocytes, as well as regulatory mechanisms that boost bile acid secretion in response to physiological or pathological stimuli.
Why Is positive regulation of bile acid secretion Important in Cell Biology?
Positive regulation of bile acid secretion is critical for maintaining bile acid homeostasis and preventing cholestatic liver injury, and its dysregulation contributes to cancer, metabolic disease, and inflammation. Bile acids are not only digestive detergents but also potent signaling molecules that influence immune cell function and tumor progression, making this process a key node in host-microbe and metabolic interactions.
• Maintains bile acid homeostasis and prevents cholestatic liver and kidney injury.
• Modulates tumor-specific T cell responses in liver cancer.
• Influences colorectal cancer growth via microbiota-modified bile acids.
• Contributes to obesity susceptibility through the bile acid-gut microbiota axis.
• Regulates innate lymphoid cell function in ulcerative colitis.
• Links microbial bile salt hydrolase activity to amine-conjugated bile acid formation.
• Mediates deoxycholic acid-induced ferroptosis and colonic inflammation.
• Supports cholangiocarcinoma colonization in lymph node metastases.
• Provides therapeutic targets for metabolic and inflammatory diseases.
• Enables CRISPR-based causal gene studies in hepatology and oncology.
What Happens During positive regulation of bile acid secretion?
Bile acid synthesis and sensing
In simple terms: The body makes bile acids and senses how much is present.
Positive regulation of bile acid secretion begins with bile acid synthesis from cholesterol, primarily via CYP7A1, and sensing of bile acid levels by nuclear receptors such as NR1H4 (FXR). In liver cancer, bile acid synthesis impedes tumor-specific T cell responses, indicating that synthesis and secretion are coupled to immune regulation.
Transcriptional activation of transporters
In simple terms: Genes that pump bile acids out of cells are turned on.
Activation of FXR induces expression of bile acid export pumps including ABCB11 (BSEP) and ABCC2 (MRP2), which increase bile acid secretion into bile canaliculi. This transcriptional program is a core mechanism of positive regulation of bile acid secretion.
Inflammatory and stress signaling
In simple terms: Inflammation and stress can boost bile acid release.
Bile acid-induced IRF3 phosphorylation mediates cell death and inflammatory responses in cholestasis, and this signaling can feed back to regulate bile acid secretion. Microbial metabolite deoxycholic acid-mediated ferroptosis exacerbates colonic inflammation, linking bile acid secretion to oxidative stress pathways.
Microbiota-dependent modification
In simple terms: Gut bacteria change bile acids and affect how they are released.
Bile salt hydrolase catalyses formation of amine-conjugated bile acids, and gut microbiota-derived 12-ketolithocholic acid suppresses IL-17A secretion from colonic group 3 innate lymphoid cells, showing that microbial modification influences bile acid secretion and immune responses. A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility, further linking microbiota to positive regulation of bile acid secretion.
Secretion and enterohepatic circulation
In simple terms: Bile acids are released and recycled between liver and gut.
Once secreted, bile acids undergo enterohepatic circulation, and their release is positively regulated by transporters such as SLC10A1 (NTCP) and ABCB11. In cholangiocarcinoma, oleic acid-PPARγ-FABP4 loop fuels colonization in lymph node metastases, indicating that lipid and bile acid secretion pathways intersect in cancer progression.
Key Genes Involved in GO:0120189 positive regulation of bile acid secretion
The following genes and proteins are experimentally implicated in the positive regulation of bile acid secretion and its associated diseases.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NR1H4 (FXR) | Nuclear receptor that induces bile acid export pumps | Target for cholestasis and metabolic disease |
| ABCB11 (BSEP) | ATP-dependent bile acid export pump | Mutations cause progressive familial intrahepatic cholestasis |
| ABCC2 (MRP2) | Canalicular export pump for bile acids | Regulated by FXR in cholestasis |
| SLC10A1 (NTCP) | Sodium-taurocholate cotransporting polypeptide | Mediates hepatic bile acid uptake |
| CYP7A1 | Rate-limiting enzyme in bile acid synthesis | Links synthesis to secretion |
| IRF3 | Kinase phosphorylated by bile acids | Mediates cell death and inflammation in cholestasis |
| ZBP1 | Sensor regulated by IRF3 in bile acid-induced injury | Involved in liver and kidney injury |
| IL-17A | Cytokine suppressed by 12-ketolithocholic acid | Modulates ulcerative colitis exacerbation |
| CD8+ T cells | Effector T cells suppressed by bile acids | Bile acids promote colorectal cancer growth |
| PPARγ | Nuclear receptor in lipid metabolism | Fuels cholangiocarcinoma colonization |
| FABP4 | Fatty acid binding protein | Part of oleic acid-PPARγ-FABP4 loop |
| Bile salt hydrolase | Microbial enzyme modifying bile acids | Forms amine-conjugated bile acids |
| 12-ketolithocholic acid | Microbiota-derived bile acid metabolite | Suppresses IL-17A from ILC3 |
| Deoxycholic acid | Microbial metabolite causing ferroptosis | Exacerbates colonic inflammation |
| Tumor-specific T cells | Immune cells affected by bile acid synthesis | Impeded during liver cancer |
| Gut microbiota | Community modifying bile acids | Contributes to obesity susceptibility |
| Oleic acid | Fatty acid influencing PPARγ-FABP4 loop | Promotes cholangiocarcinoma metastasis |
How Is positive regulation of bile acid secretion Regulated?
Positive regulation of bile acid secretion is controlled by nuclear receptor signaling, particularly FXR, which induces ABCB11 and ABCC2 expression. Inflammatory kinases such as IRF3 are phosphorylated by bile acids and regulate ZBP1, mediating cell death and fibrosis in cholestasis. Gut microbiota modify bile acids via bile salt hydrolase and produce metabolites like 12-ketolithocholic acid that suppress IL-17A, thereby influencing bile acid secretion and immune homeostasis. Metabolic signals such as oleic acid-PPARγ-FABP4 loop also regulate bile acid-related pathways in cholangiocarcinoma.
positive regulation of bile acid secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NR1H4 (FXR) | Cholestasis, metabolic disease | Knockout mouse or hepatocyte-specific KO |
| ABCB11 (BSEP) | Progressive familial intrahepatic cholestasis | Point mutation knock-in in HepG2 cells |
| IRF3 | Cholestasis-induced liver and kidney injury | Phospho-mimetic knock-in |
| CYP7A1 | Liver cancer immune evasion | Overexpression in hepatoma cells |
| PPARγ | Cholangiocarcinoma metastasis | Knockout in cholangiocarcinoma cell lines |
Liver cancer and cholestasis
Bile acid synthesis impedes tumor-specific T cell responses during liver cancer, and bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury. These findings link positive regulation of bile acid secretion to both immune evasion and tissue injury.
Colorectal cancer and ulcerative colitis
Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8+ T cell effector functions, while gut microbiota-derived 12-ketolithocholic acid suppresses IL-17A secretion to prevent acute exacerbation of ulcerative colitis. Deoxycholic acid-mediated ferroptosis exacerbates high-fat diet-induced colonic inflammation.
Obesity and metabolic disease
A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility, indicating that positive regulation of bile acid secretion is relevant to metabolic disorders. Bile salt hydrolase catalyses formation of amine-conjugated bile acids, further linking microbial bile acid modification to host metabolism.
Cholangiocarcinoma
Oleic acid-PPARγ-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment, suggesting that bile acid and lipid secretion pathways support cancer dissemination.
From positive regulation of bile acid secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FXR positively regulate bile acid secretion? | FXR knockout hepatocytes |
| Does ABCB11 mutation impair bile acid export? | ABCB11 point mutation knock-in |
| Does IRF3 phosphorylation mediate cholestatic injury? | IRF3 phospho-mimetic knock-in |
| Does CYP7A1 overexpression affect T cell responses? | CYP7A1 overexpression in liver cancer cells |
| Does PPARγ-FABP4 loop drive cholangiocarcinoma colonization? | PPARγ knockout in cholangiocarcinoma cells |
| Does microbiota modification alter bile acid secretion? | Gnotobiotic mice with bile salt hydrolase KO |
How to Study the positive regulation of bile acid secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Bile acid species and concentrations | Serum and bile analysis |
| RNA-seq | Transcriptional changes in transporters | FXR target gene expression |
| Phosphoproteomics | Kinase signaling events | IRF3 phosphorylation in cholestasis |
| CRISPR knockout screen | Gene requirement for bile acid secretion | Novel regulator discovery |
| 16S rRNA sequencing | Gut microbiota composition | Bile acid-gut microbiota axis |
| Immunohistochemistry | Protein localization in liver tissue | BSEP and MRP2 expression |
| Ferroptosis assays | Lipid peroxidation and cell death | Deoxycholic acid-induced inflammation |
Bile acid profiling
Quantitative measurement of bile acids in serum, bile, and feces using mass spectrometry is essential to assess positive regulation of bile acid secretion. This method reveals changes in bile acid pool size and composition in response to genetic or microbial perturbations.
Transcriptomics and RNA-seq
RNA sequencing of liver or intestinal cells can identify transcriptional changes in FXR target genes such as ABCB11 and ABCC2, providing readouts of positive regulation of bile acid secretion.
Proteomics and phosphoproteomics
Proteomic analysis of bile acid-treated cells can detect phosphorylation events such as IRF3 phosphorylation, linking signaling to bile acid secretion and injury.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify novel positive regulators of bile acid secretion in hepatocyte models.
How CRISPR Can Be Used to Study GO:0120189 positive regulation of bile acid secretion
Knockout
CRISPR knockout of candidate genes such as NR1H4 or ABCB11 in hepatocyte cell lines can determine whether they are required for positive regulation of bile acid secretion. Loss-of-function models reveal baseline secretion defects and compensatory pathways.
Point Mutation
Point mutation knock-in of disease-associated variants in ABCB11 or IRF3 can mimic cholestasis or altered signaling, enabling precise structure-function studies of bile acid secretion regulation.
Knock-in
Knock-in of tagged transporters or reporters allows real-time tracking of bile acid secretion dynamics in live cells. This approach can visualize BSEP trafficking and canalicular export.
Overexpression
Overexpression of CYP7A1 or PPARγ in liver cancer or cholangiocarcinoma cells can test whether increased bile acid synthesis or lipid signaling drives tumor progression and immune evasion.
How EDITGENE Supports positive regulation of bile acid secretion Research
Researchers studying positive regulation of bile acid secretion-related genes often need to determine whether a candidate gene is causally involved in bile acid export, signaling, or disease progression. EDITGENE provides CRISPR-based cell model services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of bile acid secretion research.
Frequently Asked Questions About positive regulation of bile acid secretion
What is GO:0120189?
GO:0120189 is the Gene Ontology term for positive regulation of bile acid secretion, defined as any process that activates or increases the frequency, rate or extent of the controlled release of bile acid from a cell or a tissue.
What genes are involved in positive regulation of bile acid secretion?
Key genes include NR1H4 (FXR), ABCB11 (BSEP), ABCC2 (MRP2), SLC10A1 (NTCP), and CYP7A1, which coordinate bile acid synthesis and export.
How is bile acid secretion regulated?
Bile acid secretion is positively regulated by FXR-mediated induction of export pumps, inflammatory kinases such as IRF3, and gut microbiota-derived metabolites.
What diseases are linked to bile acid secretion?
Dysregulated bile acid secretion is linked to liver cancer, cholestasis, colorectal cancer, obesity, and ulcerative colitis.
How do gut microbiota affect bile acid secretion?
Gut microbiota modify bile acids via bile salt hydrolase and produce metabolites like 12-ketolithocholic acid that influence bile acid secretion and immune responses.
What is the role of FXR in bile acid secretion?
FXR induces expression of ABCB11 and ABCC2, which are bile acid export pumps, thereby positively regulating bile acid secretion.
Can CRISPR be used to study bile acid secretion?
Yes, CRISPR knockout, knock-in, and overexpression models enable causal testing of genes involved in positive regulation of bile acid secretion.
What methods measure bile acid secretion?
Mass spectrometry, RNA-seq, phosphoproteomics, and CRISPR screens are commonly used to measure bile acid secretion and its regulation.
What is the link between bile acids and cancer?
Bile acids can suppress T cell responses and promote colorectal cancer growth, and bile acid synthesis impedes tumor-specific T cell responses in liver cancer.
How does cholestasis relate to bile acid secretion?
Cholestasis involves impaired bile acid secretion, and bile acid-induced IRF3 phosphorylation mediates cell death and fibrosis in cholestasis-induced liver and kidney injury.
Conclusion
GO:0120189, positive regulation of bile acid secretion, is a critical biological process that integrates nuclear receptor signaling, transporter activity, inflammatory pathways, and gut microbiota to control bile acid release. Its dysregulation contributes to liver cancer, cholestasis, colorectal cancer, obesity, and ulcerative colitis, making it a high-value target for mechanistic and therapeutic research. CRISPR-based cell models and multi-omics approaches provide powerful tools to dissect the causal genes and pathways that positively regulate bile acid secretion.
References
- 1. Varanasi SK et al.. 2025. Bile acid synthesis impedes tumor-specific T cell responses during liver cancer.. Science 387(6730):192-201 PMID: 39787217
- 2. Zhuang Y et al.. 2024. Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.. Hepatology 79(4):752-767 PMID: 37725754
- 3. Cong J et al.. 2024. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8(+) T cell effector functions.. Immunity 57(4):876-889.e11 PMID: 38479384
- 4. Rimal B et al.. 2024. Bile salt hydrolase catalyses formation of amine-conjugated bile acids.. Nature 626(8000):859-863 PMID: 38326609
- 5. Wei M et al.. 2020. A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility.. EBioMedicine 55:102766 PMID: 32408110
- 6. Li N et al.. 2023. Gut microbiota-derived 12-ketolithocholic acid suppresses the IL-17A secretion from colonic group 3 innate lymphoid cells to prevent the acute exacerbation of ulcerative colitis.. Gut Microbes 15(2):2290315 PMID: 38062857
- 7. Wang C et al.. 2024. Microbial metabolite deoxycholic acid-mediated ferroptosis exacerbates high-fat diet-induced colonic inflammation.. Mol Metab 84:101944 PMID: 38642891
- 8. Zhang H et al.. 2024. Oleic acid-PPARγ-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment.. Hepatology 80(1):69-86 PMID: 38377465
